StockGuru News: The Immune Response Corporation (OTCBB: IMNR) Receives Approval for Expansion of Phase II Trial in France for Investigative HIV Immunotherapy IR103
The Immune Response Corporation (OTCBB: IMNR) The Immune Response Corporation Receives Approval for Expansion of Phase II Trial in France for Investigative HIV Immunotherapy IR103 CARLSBAD, Calif.–Aug. 1, 2006–The Immune Response Corporation (OTCBB: IMNR) announced today the receipt of approvals to expand its Phase II IR103 study in drug-naive HIV patients to include clinical sites in France. The trial, which is currently ongoing at several sites in Italy, will examine IR103, a second-generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended for antiretroviral therapy according to current medical guidelines. Ultimately, more than 200 drug-naive patients will…